Research Applications for Striatech Products

Optic Nerve Damage

Axonopathy across acute trauma, chronic glaucomatous pressure, and demyelinating injury. Defined molecular cascades, like SARM1 activation, zinc toxicity, RGC soma death, produce functional consequences detectable before structural loss is irreversible.
Introduction

What is Optic Nerve Damage?

Optic nerve damage encompasses the structural and functional disruption of retinal ganglion cell (RGC) axons as they project from the retina to the brain, and it occurs across a remarkably broad range of disease contexts. Mechanistically, the defining event is axonopathy: the progressive disconnection and degeneration of long-projection RGC axons, mediated through pathways that include pro-degenerative NAD+ depletion (the SARM1/NMNAT axis), disrupted axon transport, demyelination, ischaemia, and metabolic failure. The functional consequence is loss of visual acuity and contrast sensitivity that can be quantified non-invasively and longitudinally in awake, freely moving rodents using the optomotor reflex. This page focuses specifically on optic nerve damage as a mechanism shared across multiple disease contexts, including glaucoma, acute traumatic injury, inflammatory demyelination, inherited optic neuropathies, toxic insults, and systemic neurodegenerative disease. Optic nerve damage is covered as a mechanism within each of the following application areas: Glaucoma and Optic Nerve Neurodegeneration, Trauma and Acute Injury, Neuroinflammation and Autoimmune CNS Disease, Ocular Inflammation and Immune-Mediated Eye Disease, Rare and Inherited CNS and Eye Disorders, Retinal Degeneration and Inherited Retinal Disease, Neurodegenerative Disease, Systemic Aging and CNS Decline, Myopia, Refractive Development and Eye Growth, and Ocular and CNS Toxicity Models. For therapeutic approaches targeting optic nerve neuroprotection and regeneration, see also Maintaining and Restoring Vision.
Animal Models

What Are Common Animal Models For Optic Nerve Damage?

The following models have documented optic nerve axonopathy with published OptoDrum functional data in the Striatech corpus. Models listed on parent application pages solely because of the broader disease area – without specific optic nerve axon pathology confirmed by this cluster's publications – are omitted here. For the full model landscape of each disease context, consult the relevant parent application page.
  • Optic nerve crush (ONC) in mice and rats. The ONC model is the workhorse cross-context model for optic nerve axonopathy, inducing acute, synchronised Wallerian-like axon degeneration followed by a defined window for neuroprotective and regenerative intervention. Functional visual acuity drops sharply within days of crush and can be tracked longitudinally by OptoDrum; partial recovery is detectable with high sensitivity if axon regeneration or neuroprotection is achieved. Used across the trauma, glaucoma, and vision restoration contexts in this corpus.
  • Microbead or laser-induced ocular hypertension glaucoma models. Chronic elevation of intraocular pressure induces progressive, IOP-driven RGC axon degeneration that mirrors glaucomatous optic neuropathy. OptoDrum captures the progressive functional decline over weeks to months, enabling both disease trajectory mapping and neuroprotective/gene-therapeutic efficacy studies. Documented in Mickevicius et al. (2025), Li et al. (2025), Zhao et al. (2025), and others.
  • PLP-deficient and proteolipid protein mutation models (jimpy, rumpshaker). Mutations in proteolipid protein cause primary CNS hypomyelination and secondary optic nerve axon degeneration. These models are relevant to the inflammatory demyelination axis of optic nerve damage, and OptoDrum has been used to document the functional visual consequences of both progressive demyelination and the counter-intuitive protective demyelination demonstrated in Groh et al. (2023).
  • EAE (experimental autoimmune encephalomyelitis) and MOG-immunisation models. EAE induces inflammatory optic nerve demyelination that closely mirrors the optic neuritis seen in multiple sclerosis. OptoDrum reliably detects functional visual deficits in EAE, and recent work by Groh et al. (2025) has mapped the CX3CR1-dependent microglial mechanism of optic nerve demyelination in a combined aging-EAE model. The Capper et al. (2025) study further demonstrates OptoDrum sensitivity to diet-induced modulation of EAE visual outcomes.
  • Wfs1-mutant mice (Wolfram syndrome model). Wfs1-deficient mice develop progressive optic nerve degeneration driven by MCT1-dependent metabolic failure and secondary neuroinflammation, as characterised in Rossi et al. (2023). OptoDrum provides longitudinal functional monitoring of disease progression in this inherited optic neuropathy model.
  • PNPLA6 / NTE-deficient mice. Loss of neuropathy target esterase (NTE/PNPLA6) causes a hereditary spastic paraplegia / optic atrophy phenotype. OptoDrum-based functional decline was characterised alongside histological optic nerve pathology in Liu et al. (2024), establishing this as a relevant rare-disease optic nerve damage model.
  • Aging rodents with progressive optic nerve amyloid or glaucomatous changes. Aged mice accumulate beta-amyloid within the optic nerve and show progressive axon degeneration, as documented in Oh et al. (2025). These models bridge the neurodegenerative and aging contexts of optic nerve damage and are amenable to longitudinal OptoDrum monitoring.
Research Questions

How Can Striatech Tools support Your Study?

Select a question that matches your research objective to see which instruments are relevant, what challenge they address, and what the published evidence shows.
01
What Are the Molecular Mechanisms of Optic Nerve Axon Degeneration, and Can OptoDrum Detect the Onset Before Structural Loss Is Irreversible?
Audience A - Vision-focused

Quick Answer

Optic nerve axon degeneration proceeds through defined molecular steps – including SARM1-mediated NAD+ depletion, zinc-triggered axon toxicity, and progressive RGC soma death – and OptoDrum detects the functional consequences of axon loss with sensitivity sufficient to resolve the onset and progression of degeneration in IOP-elevation and ONC models. For a broader view of RGC-specific death pathways, see Retinal Ganglion Cell Death and for functional correlates of RGC dysfunction, see Retinal Ganglion Cell Dysfunction.

The challenge

Optic nerve axon degeneration is not a single event but a multi-step process with distinct molecular phases. Following injury or chronic IOP elevation, SARM1 activation triggers rapid NAD+ depletion within the axon, initiating Wallerian-like degeneration that proceeds independently of the RGC soma. Zinc released from damaged axons can propagate secondary toxicity. Disrupted axon transport precedes soma death, and reactive gliosis alters the periaxonal microenvironment. Each step represents a potential therapeutic target, and each step could, in principle, be detected as a functional inflection point if a sensitive enough behavioural readout is available.

The challenge for researchers is two-fold: first, to identify which molecular step is rate-limiting for visual loss in a specific model; and second, to determine whether a pharmacological or genetic intervention at one step is sufficient to preserve or restore functional visual performance. Histological endpoints (RGC counting, axon quantification) are terminal, require skilled interpretation, and cannot be repeated over time in the same animal. Electrophysiological endpoints (flash VEP, pattern ERG) require anaesthesia and technically demanding surgery. Longitudinal functional readouts that can be repeated non-invasively in the same animal across the full course of axon degeneration have therefore been critical for this field.

How Striatech products help

OptoDrum

Measures spatial visual acuity (cycles per degree) and contrast sensitivity threshold via the subcortical optomotor reflex in awake, freely moving rodents. Provides a non-invasive, repeatable functional readout of the retina-to-brainstem pathway integrity – sensitive to the progressive axon loss and RGC dysfunction that characterise optic nerve degeneration. Can resolve the time course of functional decline in IOP-elevation glaucoma models and post-ONC, enabling therapeutic window identification. Note: OptoDrum measures subcortical optomotor responses, not cortical visual processing.

AcuiSee

Measures visual acuity via operant visual-reward paradigm requiring cortical visual processing. Applicable where researchers need to assess whether axon degeneration impacts suprathreshold visual perception and cortical integration of visual input, beyond what the subcortical optomotor reflex captures. No publications yet in this specific context; inclusion is based on product capability.

DarkAdapt

Provides controlled dark-adaptation prior to scotopic OptoDrum testing (with ScotopicKit), enabling rod-pathway-specific functional assessment in optic nerve damage models where rod vs. cone pathway contributions to visual loss are of interest.

Non-aversive Animal Platform

Minimises handling stress for post-surgical or debilitated animals – important after ONC or in chronic optic neuropathy models where baseline stress confounds longitudinal visual function measurements.

Evidence from the Literature

  • Kinuthia et al (2025) JCI Insight.
  • Mickevičius et al (2025) Exp Eye Res.

    Systematically mapped the time course over which structural RGC loss (histology, axon counts, optic nerve pathology) correlates with functional visual acuity measured by OptoDrum. Established OptoDrum as a validated functional correlate of optic nerve axon damage in a fully characterised glaucoma model.

  • Liu et al (2023) Neural Regen Res.

    Demonstrated that targeting zinc-mediated axon toxicity – a defined step in the post-injury axon degeneration cascade – reduces structural axon loss and preserves OptoDrum-measured visual acuity. Provides direct evidence that OptoDrum is sensitive to axon-targeted molecular interventions.

  • Baya Mdzomba et al (2020) Cell Death Dis.
    Journal Club →

    Targeted the canonical axon regeneration inhibitor Nogo-A and demonstrated OptoDrum-confirmed functional recovery in an inflammatory optic nerve damage model. Provides a benchmark for anti-regeneration-inhibitor strategies with functional validation.

  • Zeng et al (2024) Acta Neuropathol Commun.

    For the SARM1 axis of axon degeneration specifically, it has been demonstrated that loss of SARM1 reduces RGC death and optic nerve axon degeneration in a glaucoma model, with OptoDrum used to assess functional outcomes.

02
How Does Inflammatory Demyelination of the Optic Nerve Differ Mechanistically from Traumatic Axonopathy, and Do These Mechanisms Produce Distinguishable Functional Signatures?
Audience A - Vision-focused
Audience B - CNS/Systemic

Quick Answer

Inflammatory demyelination (as in optic neuritis and EAE) and traumatic axonopathy (as in ONC) activate overlapping but distinct downstream pathways, and OptoDrum can detect functional visual loss in both paradigms. Molecular dissection using knockout models (CX3CR1, SARM1, TNF-α signalling) has begun to reveal whether the functional trajectory – onset kinetics, depth of loss, recovery potential – differs between these two broad mechanisms. For the broader optic neuritis literature, see Optic Neuritis.

The challenge

Optic neuritis in MS and inflammatory optic neuropathy models (EAE, MOG-immunisation) share surface similarity with traumatic optic nerve crush in producing functional visual loss, but the underlying biology is fundamentally different. In traumatic ONC, axon degeneration is triggered by a discrete mechanical insult and proceeds through Wallerian-like degeneration distal to the crush site, with the inflammatory response secondary. In inflammatory demyelination, microglia and infiltrating immune cells are primary actors: demyelination precedes axon loss, and the relationship between myelin removal and axon damage is not simple (as demonstrated by the Groh 2023 Nat Commun study showing that controlled microglial demyelination can actually protect against secondary axon degeneration). In EAE, the CX3CR1-dependent microglial signalling cascade orchestrates demyelination in a way that is age-modulated and distinct from crush-triggered axon loss.

The practical challenge for researchers is that available visual functional readouts in rodents have not historically been able to disambiguate the two mechanisms at the level of the functional signature. Whether the onset kinetics, depth, or recovery profile of OptoDrum-measured visual loss differs between inflammatory and traumatic optic nerve damage – and whether this could serve as a model-distinguishing criterion – is an open question that recent publications in this corpus begin to address.

For the EAE/MS optic nerve context more broadly, see Neuroinflammation and Autoimmune CNS Disease. For immune-mediated optic neuropathy, see Ocular Inflammation and Immune-Mediated Eye Disease.

How Striatech products help

OptoDrum

Provides a non-invasive, repeatable functional readout of the retina-to-brainstem optomotor pathway in both inflammatory (EAE, optic neuritis) and traumatic (ONC, IOP-elevation) models. Longitudinal testing in the same animals resolves the kinetics of functional decline and recovery in each paradigm – a prerequisite for comparing inflammatory vs. traumatic signatures. Sensitive to diet-induced differences in EAE severity (Capper et al. 2025) and to microglial-axis-specific manipulation (Groh et al. 2025).

AcuiSee

For studies assessing whether inflammatory vs. traumatic mechanisms differentially impact cortical visual processing beyond subcortical reflexes, AcuiSee’s operant cortical paradigm provides a complementary higher-level visual endpoint. Capability-based inclusion; no cluster-specific publications yet.

Non-aversive Animal Platform

Reduces confounding stress in longitudinal experiments comparing disease trajectories across EAE and ONC cohorts, particularly when repeated testing over weeks is required.

Evidence from the Literature

  • Kinuthia et al (2025) JCI Insight.
  • Groh et al (2025) Nat Neurosci.
    Journal Club →
    Feature →

    Identification of the CX3CR1 signalling axis as the microglial driver of optic nerve demyelination in a combined aging-autoimmune model, with OptoDrum documenting the functional visual decline across the demyelination time course.

  • Groh et al (2023) Nat Commun.
    Feature →

    Demonstration of a counter-intuitive protective role for controlled microglia-mediated demyelination: in PLP-deficient mice, microglial myelin removal actually reduces secondary axon degeneration, with OptoDrum confirming preservation of functional visual acuity. Directly challenges the assumption that inflammatory demyelination always leads to axon loss.

  • Capper et al (2025) Front Immunol.

    Showed that dietary modulation of EAE severity produces detectable between-group differences in OptoDrum-measured visual function, validating OptoDrum sensitivity to graded inflammatory optic nerve damage.

  • Li et al (2025) Neurosci Bull.

    TNF-α was established as a specific cytokine mediator of optic nerve damage and RGC death in a glaucoma model, with OptoDrum confirming functional visual loss alongside structural RGC counts. Demonstrates molecular-level dissection of the inflammatory contribution to optic nerve axonopathy with a specific functional outcome.

03
How Can Optic Nerve Crush Serve as a Cross-Context Workhorse Model for Traumatic, Ischemic, and Regenerative Optic Nerve Research, and Which Functional Readouts Apply?
Audience A - Vision-focused

Quick Answer

Optic nerve crush (ONC) induces synchronised, reproducible axon degeneration that is mechanistically informative across traumatic, ischaemic, and regenerative research contexts, and OptoDrum provides the key functional endpoint – capable of detecting not only the post-injury nadir of visual loss but also incremental, partial recovery above that floor when regenerative or neuroprotective interventions are applied. For therapeutic recovery strategies, see also Maintaining and Restoring Vision.

The challenge

ONC is used in multiple research contexts simultaneously: as a model of traumatic optic neuropathy, as a proxy for ischaemia-reperfusion injury (given shared downstream apoptotic pathways), and as the most widely adopted model for testing optic nerve axon regeneration strategies. The versatility of ONC creates a challenge: functional outcome measures need to be sensitive enough to detect partial, incremental recovery above the post-injury floor – not only complete functional restoration, which is rarely achieved with current regenerative approaches. A readout that can only resolve “normal vs. fully blind” is insufficient; the field needs endpoints that detect partial, functionally meaningful gains.

Additionally, functional endpoints in ONC research have historically relied on invasive, terminal, or low-throughput methods (flash VEP under anaesthesia, pattern ERG, RGC counting after sacrifice). The inability to track the same animal longitudinally over the full post-crush recovery window – which can span 4-8 weeks – has been a limiting factor in understanding the temporal dynamics of functional recovery in response to interventions.

For the broader trauma and acute injury context, see Trauma and Acute Injury.

How Striatech products help

OptoDrum

Provides automated, non-invasive, longitudinal measurement of spatial visual acuity and contrast sensitivity in awake mice and rats after ONC. Sensitive to the post-ONC nadir (typically 0.1-0.15 cycles/degree in mice, vs. ~0.5 c/deg pre-crush) and to incremental recovery above that floor when regenerative interventions succeed. Enables repeated measurement at weekly intervals in the same animal, removing the inter-animal variability of terminal endpoint-only designs. Measures subcortical optomotor pathway integrity, not cortical visual processing.

AcuiSee

For ONC studies evaluating whether regenerated axons restore cortically integrated visual perception – not just subcortical reflex responses – AcuiSee’s operant paradigm provides a higher-level visual endpoint. Capability-based inclusion; no ONC-specific publications yet.

Non-aversive Animal Platform

Post-surgical animals after ONC may exhibit altered stress responses and handling sensitivity; the non-aversive platform reduces stress confounds during longitudinal visual function testing over the recovery window.

Evidence from the Literature

  • Kinuthia et al (2025) JCI Insight.
  • Varadarajan et al (2023) Cell Rep.
    Journal Club →

    Demonstrated that enhancing postsynaptic activity in visual brain targets promotes RGC axon regeneration after ONC, and critically showed that this anatomical regeneration translates to functional recovery detectable by OptoDrum above the post-ONC floor.

  • Zhang et al (2024) Sci Adv.

    Identified a novel intraretinal dopaminergic mechanism promoting post-ONC functional recovery, with OptoDrum tracking the recovery trajectory longitudinally. Demonstrates that functional recovery can be achieved via intraretinal circuit targets, not only via direct axon regeneration approaches.

  • Eghbali et al (2023) Cell J.

    Demonstrated multi-target EPO neuroprotection (anti-apoptotic, anti-inflammatory, glial-suppressive) after optic nerve injury, with OptoDrum confirming that cellular-level protection translates to preserved optomotor visual performance.

  • Li et al (2023) Life Sci. Alliance
    Feature →

    Supporting evidence for OptoDrum sensitivity to antioxidant neuroprotection strategies in optic nerve injury, with ascorbic acid-treated animals showing preserved visual acuity relative to controls.

04
Do Rare Inherited and Metabolic Optic Neuropathies Follow the Same Functional Trajectory as Acquired Optic Nerve Injury, and How Can Visual Readouts Support Longitudinal Disease Monitoring?
Audience A - Vision-focused
Audience B - CNS/Systemic

Quick Answer

Rare inherited optic neuropathies – from Wolfram syndrome (MCT1/metabolic failure) to PNPLA6-related optic atrophy to myopia-associated secondary optic nerve stretch – produce progressive functional visual decline measurable by OptoDrum, and the longitudinal, non-invasive nature of optomotor testing makes it particularly suited to rare disease model phenotyping, where animal numbers are limited and repeated within-subject measurements are critical. For the broader rare disease context, see Rare and Inherited CNS and Eye Disorders, and for neurodegenerative mechanisms involving optic nerve amyloid pathology, see Neurodegenerative Disease.

The challenge

Rare inherited optic neuropathies present distinct phenotyping challenges: animal models often have small group sizes due to breeding constraints; disease progression may be slow and heterogeneous; and the primary pathological mechanism (metabolic failure, structural gene mutation, amyloid deposition, or axial elongation) may not be immediately separable from secondary downstream events (neuroinflammation, oxidative stress, vascular compromise). The question of whether a rare inherited optic neuropathy follows the same functional trajectory as acute acquired injury – or whether its distinct molecular mechanism produces a different optomotor signature – is of direct scientific and translational relevance.

In Wolfram syndrome (Wfs1-mutant mice), the primary driver is MCT1-dependent metabolic failure followed by secondary neuroinflammation; in PNPLA6-deficient mice, NTE loss disrupts membrane phospholipid homeostasis; in high-myopia models with progressive axial elongation, mechanical stretch and secondary vascular changes drive optic nerve damage. These mechanisms differ from traumatic crush or ischaemia-reperfusion, yet all converge on progressive RGC axon degeneration and measurable optomotor decline. Establishing whether the functional trajectory is mechanistically distinguishable requires longitudinal readouts with sufficient sensitivity to resolve slow, graded progression.

For inherited conditions involving optic nerve and CNS involvement more broadly, see Rare and Inherited CNS and Eye Disorders. For the aging-associated and Alzheimer’s disease context, see Systemic Aging and CNS Decline and Neurodegenerative Disease. For the high myopia structural context, see Myopia, Refractive Development and Eye Growth.

How Striatech products help

OptoDrum

Provides automated, non-invasive longitudinal measurement of spatial visual acuity in rare disease models, enabling repeated within-subject monitoring across the full natural history of progressive optic nerve damage. Particularly valuable in low-n rare disease cohorts where terminal endpoint variability must be minimised. Sensitivity to slow, graded decline (as opposed to acute crush) has been documented in Wolfram syndrome and PNPLA6-deficient models. Measures subcortical optomotor pathway integrity.

ScotopicKit

Enables scotopic (dark-adapted, rod-pathway) optomotor measurement in rare disease models where rod pathway involvement is relevant (e.g. conditions with dual rod-cone phenotypes or conditions where optic nerve damage differentially affects rod- vs. cone-driven pathways).

AcuiSee

For inherited optic neuropathies where the question is whether cortical visual processing is differentially affected by genetic optic nerve damage, AcuiSee’s operant paradigm provides cortical-level assessment. Capability-based inclusion; no rare optic neuropathy publications yet.

Non-aversive Animal Platform

Important for debilitated or systemically affected rare disease model mice that may have confounding systemic disease burden (e.g. Wolfram syndrome mice with diabetes insipidus, neurological co-phenotypes); minimises stress confounds in longitudinal studies.

Evidence from the Literature

  • Kinuthia et al (2025) JCI Insight.
  • Rossi et al (2023) Elife

    Characterised the metabolic failure (MCT1 deficiency) and secondary neuroinflammation driving optic nerve degeneration in Wfs1-mutant mice, with OptoDrum tracking visual acuity longitudinally as a non-invasive disease progression biomarker.

  • Liu et al (2024) Brain.

    Characterised progressive optic nerve damage, retinal dystrophy, and visual function decline in NTE/PNPLA6-deficient mice (a model of Gordon Holmes / Oliver McFarlane syndrome), with OptoDrum providing the ocular phenotyping alongside histological endpoints.

  • Oh et al (2025) J Korean Ophthalmol Soc.

    Characterised optic nerve amyloid deposition and associated axonal degeneration in aging/AD mouse models, with OptoDrum documenting the functional visual decline corresponding to amyloid infiltration of the optic nerve.

  • Insignares et al (2025) Int J Mol Sci.

    Characterised progressive axial elongation producing secondary optic nerve stretch and RGC dysfunction across the intersection of myopia, glaucoma, and aging, with OptoDrum confirming functional visual circuit consequences.

05
Can Precision Molecular Neuroprotection Strategies – Including Gene Editing and Targeted Cytokine Blockade – Preserve Functional Vision After Optic Nerve Damage, and Does OptoDrum Resolve Between-Treatment Differences?
Audience A - Vision-focused
Audience B - CNS/Systemic

Quick Answer

High-fidelity RNA-targeting gene editing, anti-Nogo-A antibodies, EPO neuroprotection, and TNF-α blockade have all been shown to preserve or partially restore OptoDrum-measured visual acuity in optic nerve damage models, validating OptoDrum as a clinically translatable functional endpoint for molecular neuroprotection studies. For therapeutic gene therapy and vision restoration strategies in a broader context, see Maintaining and Restoring Vision.

The challenge

Neuroprotective and regenerative strategies for optic nerve damage span a wide range of molecular targets: gene editing to silence pathogenic expression (e.g. RNA-targeting Cas13 systems), neutralisation of axon growth inhibitors (Nogo-A antibodies), cytokine blockade (anti-TNF-α), antioxidant supplementation (vitamin C, EPO), and circuit-level neuromodulation (amacrine cell dopamine signalling). Demonstrating that these diverse interventions produce functionally meaningful visual preservation – beyond structural RGC count improvements – requires a sensitive, non-invasive functional readout that can be applied repeatedly across large intervention cohorts.

A critical translational question is whether functional preservation detected by OptoDrum correlates with RGC survival histology on a study-by-study basis, and whether OptoDrum can resolve the between-group differences anticipated from molecularly targeted interventions that may only partially protect the RGC population. The Mickevicius et al. (2025) study provides the definitive structure-function calibration reference for this question. The Zhao et al. (2025) gene-editing study and the Baya Mdzomba et al. (2020) anti-Nogo-A study provide the direct interventional evidence.

How Striatech products help

OptoDrum

Provides the automated, quantitative functional endpoint for molecular neuroprotection studies: measures spatial acuity and contrast sensitivity as direct readouts of how well RGC axons are functioning after treatment. Sensitive to partial neuroprotection (i.e. can distinguish treated from vehicle-control groups even when protection is incomplete). Non-invasive and repeatable, enabling longitudinal tracking to identify the therapeutic window and the durability of protection. Subcortical optomotor pathway measurement; for cortical endpoint see AcuiSee.

AcuiSee

For gene-editing and neuroprotection studies where the translational question is whether cortical visual processing is preserved alongside subcortical reflex recovery, AcuiSee’s operant visual discrimination paradigm provides the cortical-level functional endpoint. Capability-based inclusion; no publications yet in precision molecular neuroprotection context.

Non-aversive Animal Platform

Relevant for post-gene-delivery animals (intravitreal injection, subretinal delivery) where handling stress could confound early post-delivery functional assessments; provides a standardised, stress-minimised testing condition.

Evidence from the Literature

  • Kinuthia et al (2025) JCI Insight.
  • Zhao et al (2025) Adv Sci (Weinh).

    Developed and applied a high-fidelity RNA-targeting CRISPR-Cas13 system to silence pathogenic gene expression in a glaucoma/optic nerve damage model, with OptoDrum measuring visual acuity alongside RGC survival as the primary outcome.

  • Baya Mdzomba et al (2020) Cell Death Dis.
    Journal Club →

    Demonstrated that anti-Nogo-A antibody treatment overcomes the canonical CNS axon regeneration inhibitor in an inflammatory optic nerve damage model, with OptoDrum confirming preserved or recovered visual function.

  • Eghbali et al (2023) Cell J.

    EPO neuroprotection with glial-suppressive and anti-apoptotic effects in optic nerve injury, with OptoDrum confirming that cellular-level protection translates to preserved optomotor acuity.

  • Li et al (2025) Neurosci Bull.

    Characterised TNF-α as a specific cytokine target in optic nerve damage, with OptoDrum documenting functional visual loss alongside structural RGC death.

Product Fit

Summary: Striatech Products supporting your research questions

Research Question OptoDrum ScotopicKit AcuiSee Photorefractor Keratometer DarkAdapt Non-aversive platform
Axon degeneration mechanisms and functional detection Yes Yes Yes Yes
Inflammatory vs. traumatic axonopathy signatures Yes Yes Yes
ONC as cross-context model; functional recovery Yes Yes Yes
Rare inherited optic neuropathies; longitudinal monitoring Yes Yes Yes Yes Yes
Molecular neuroprotection and gene-editing strategies Yes Yes Yes
Notes: Photorefractor and Keratometer are not applicable in optic nerve damage contexts – they measure refractive state (diopters) and corneal curvature respectively, neither of which is a primary endpoint for axon degeneration or RGC pathway integrity. ScotopicKit is relevant where rod-pathway-specific functional assessment is needed in rare disease models or where scotopic sensitivity is an additional phenotyping endpoint.
Measurement Modalities

Measuring Functional Visual Outcomes in Optic Nerve Damage: How Do Available Methods Compare?

Modality Invasiveness Repeatability Training required Automation 3Rs impact Scope in optic nerve damage
OptoDrum (optomotor reflex) Non-invasive; awake, unrestrained animal High; same animal weekly without anaesthetic recovery Low; automated threshold tracking Fully automated threshold determination Supports Replacement (vs. terminal histology for some questions) and Refinement Subcortical retina-to-brainstem pathway; measures acuity and contrast sensitivity
AcuiSee (operant visual discrimination) Non-invasive; reward-based operant task High after training; repeatable longitudinally Moderate; animal training required (days to weeks) Automated task delivery Refinement; reward-based, stress-minimised Cortical visual processing; operant suprathreshold perception
Flash VEP / pattern ERG Invasive (anaesthesia, electrode placement) or topical anaesthetic for ERG Moderate; anaesthesia confounds repeated measurements High; requires electrophysiology expertise Semi-automated signal acquisition Anaesthesia use; moderate refinement possible VEP: cortical; pattern ERG: RGC-specific; directly measures RGC function
RGC histology (flatmount counting, immunohistochemistry) Terminal None (terminal) Moderate; cell counting can be automated with software Semi-automated cell counting available Reduction of cohort size; terminal sacrifice required Structural gold standard for RGC survival; no functional information
OCT (optical coherence tomography) Requires topical anaesthetic or sedation for high resolution Moderate; technically demanding for repeated use High; equipment and image analysis expertise needed Semi-automated layer segmentation Refinement possible; equipment access may limit use RNFL thickness as structural proxy for axon loss; no direct functional measure
OptoDrum and electrophysiological methods are complementary rather than redundant in optic nerve damage research: OptoDrum captures the integrated subcortical pathway outcome non-invasively across repeated time points, while ERG and VEP provide RGC-layer-specific and cortical-level information that OptoDrum does not assess. Combining OptoDrum longitudinal tracking with a single terminal electrophysiological and histological endpoint typically provides both functional trajectory data and mechanistic structural confirmation within the same study design.
Supported by Striatech Products

Publications on Optic Nerve Damage

Great Research, Interactive

Journal Clubs related to Optic Nerve Damage

Featured image for “Journal Club: Aging and Injured Retinal Ganglion Cells Can Be Rejuvenated by Epigenetic Reprogramming”
Watch now
Thursday, 27 Feb 2025

Journal Club: Aging and Injured Retinal Ganglion Cells Can Be Rejuvenated by Epigenetic Reprogramming

Image
Bruce R. Ksander, Ph.D. - Schepens Eye Institute of Mass Eye & Ear, Harvard Medical School, Department of Ophthalmology
Image
This Journal Club highlights groundbreaking work by Harvard Medical School scientist Bruce R. Ksander and his team. They were able to reverse aging in retinal ganglion cells, improving visual function after injury or in disease.
Keep exploring

Related application areas, neighbouring research chapters, and the questions researchers ask most.

Application Area

Optic Nerve Damage

Axonopathy across acute trauma, chronic glaucomatous pressure, and demyelinating injury. Defined molecular cascades, like SARM1 activation, zinc toxicity, RGC soma death, produce functional consequences detectable before structural loss is irreversible.

10
Research Chapters
5
FAQs answered
Main Field where Optic Nerve Damage is studied
Glaucoma and Optic Nerve Neurodegeneration
Other relevant fields
CNS Trauma and Acute Injury: TBI, Optic Nerve Injury, Stroke
Myopia, Refractive Development and Eye Growth
Neurodegenerative Disease: Alzheimer’s, Parkinson’s and Beyond
Neuroinflammation and Autoimmune CNS Disease
Ocular and CNS Toxicity Models
Ocular Inflammation and Immune-Mediated Eye Disease
Rare and Inherited CNS and Eye Disorders
Retinal Degeneration and Inherited Retinal Disease
Systemic Aging and CNS decline